I. Vergote

发表

Exposure–response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection

B. Karlan, E. Rasmussen, I. Vergote, 2012, Cancer Chemotherapy and Pharmacology.

Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment.

A. Howell, B. Erikstein, J. Robertson, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase 1b, open-label study of trebananib in combination with paclitaxel and carboplatin in patients with ovarian cancer receiving interval or primary debulking surgery.

S. Wong, I. Vergote, J. Baurain, 2014, European journal of cancer.

Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents.

I Vergote, I. Vergote, P Abram, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Long‐term follow‐up confirms a survival advantage of the paclitaxel–cisplatin regimen over the cyclophosphamide–cisplatin combination in advanced ovarian cancer

M. Piccart, K. Swenerton, I. Vergote, 2003, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group.

M. Piccart, M. Nooij, M. Franchi, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial

B. Monk, I. Vergote, S. Chan, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval

B. Monk, I. Vergote, S. Chan, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Is there a role for neoadjuvant chemotherapy in the treatment of stage IV serous endometrial carcinoma?

F. Amant, P. Moerman, I. Vergote, 2005, International Journal of Gynecologic Cancer.

Alpha-particle radiotherapy with 211At-labeled monodisperse polymer particles, 211At-labeled IgG proteins, and free 211At in a murine intraperitoneal tumor model.

I. Vergote, K. Nustad, R. Larsen, 1995, Gynecologic Oncology.

D-TRP-6-LHRH (Triptorelin) is not effective in ovarian carcinoma: an EORTC Gynaecological Cancer Co-operative Group Study

M. Piccart, M. Nooij, M. Namer, 2001, Anti-cancer drugs.

PTEN mutations in uterine sarcomas.

F. Amant, I. Vergote, E. J. van Rensburg, 2002, Gynecologic oncology.

A Review of the Efficacy of Anastrozole in Postmenopausal Women with Advanced Breast Cancer with Visceral Metastases

A. Howell, J. Robertson, I. Vergote, 2003, Breast Cancer Research and Treatment.

Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group.

M. van Glabbeke, M. Piccart, D. Lacombe, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)--a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG.

E. Eisenhauer, I. Vergote, G. Kristensen, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

What is the role of dose-dense therapy?

J. Verweij, I. Vergote, H. V. van Doorn, 2005, International Journal of Gynecologic Cancer.

Prognostic significance of L1CAM in ovarian cancer and its role in constitutive NF-κB activation.

P. Altevogt, R. Zeillinger, T. Hielscher, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Large-scale genomic instability predicts long-term outcome for women with invasive stage I ovarian cancer.

I Vergote, H E Danielsen, V. Abeler, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Statistical controversies in clinical research: the importance of importance.

M. Schemper, R. Zeillinger, I. Vergote, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100.

P. Jelinic, R. Cristescu, G. Sonke, 2023, Gynecologic Oncology.

Trocar implantation metastasis after laparoscopy in patients with advanced ovarian cancer: can the risk be reduced?

P. V. van Dam, W. Tjalma, I. Vergote, 1999, American journal of obstetrics and gynecology.

Effect of laparoscopic surgery for moderate and severe endometriosis on depression, relationship satisfaction and sexual functioning: comparison of patients with and without bowel resection.

A. Wolthuis, C. Meuleman, C. Tomassetti, 2013, Human reproduction.